American Capital Management Inc. Sells 6,427 Shares of Medpace Holdings, Inc. $MEDP

American Capital Management Inc. lessened its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 217,947 shares of the company’s stock after selling 6,427 shares during the quarter. Medpace comprises 5.6% of American Capital Management Inc.’s investment portfolio, making the stock its biggest holding. American Capital Management Inc.’s holdings in Medpace were worth $104,656,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC increased its holdings in shares of Medpace by 164.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock valued at $2,086,000 after acquiring an additional 2,274 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in shares of Medpace during the fourth quarter worth approximately $4,084,000. Cerity Partners LLC lifted its holdings in shares of Medpace by 41.0% in the 4th quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after purchasing an additional 23,530 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Medpace by 24,930.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after purchasing an additional 100,968 shares in the last quarter. Finally, UBS Group AG grew its position in Medpace by 32.8% in the 4th quarter. UBS Group AG now owns 328,879 shares of the company’s stock valued at $184,715,000 after purchasing an additional 81,250 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Stock Performance

Medpace stock opened at $589.37 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The stock has a market cap of $16.45 billion, a PE ratio of 34.55, a price-to-earnings-growth ratio of 2.68 and a beta of 1.15. The firm’s 50-day simple moving average is $495.46 and its 200 day simple moving average is $493.70.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter last year, the business posted $3.10 EPS. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, analysts predict that Medpace Holdings, Inc. will post 17.59 EPS for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and boosted their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Royal Bank Of Canada boosted their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $535.00 target price on shares of Medpace in a report on Thursday. Two research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $560.92.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.